Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study
Objective: Use heatmap analysis to quantify and examine diurnal patterns of OFF and GOOD ON time periods throughout the day, and changes in the number…Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays
Objective: Characterize the functional activity of apomorphine relative to dopamine using a modern panel of G protein-coupled receptor biosensor assays. Background: The structural similarity of…AI for Personalized Medication Management in Parkinson’s Disease
Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line
Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD
Objective: To identify EEG source level differences between patients with Parkinson's disease (PD) and associated impulse control disorders (ICD) and patients without ICD. Background: Previous…Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.
Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…Medication Refractory Restless Legs Syndrome: Real-World Experience
Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »